Compare Revvity Inc (RVTY) vs S&P500 ETF (SPY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs S&P500 ETF — how do they compare? Revvity Inc trades at $154.1 (market cap $16.98B), while S&P500 ETF trades at $778.65 (market cap $821.54B). The key difference: S&P500 ETF is far larger — about 48.4× Revvity Inc's market cap, and Revvity Inc pays a 0.18% dividend while S&P500 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 12 Days and S&P500 ETF for 205 Days on average.
| RVTY | SPY | |
|---|---|---|
Market Cap | $16.98B | $821.54B |
Volume | 1,456,900 | 40,070,358 |
Sector | Health | — |
52-Week High | $157.36 | $779.14 |
52-Week Low | $82.26 | $631.99 |
Typical Hold Time | 12 Days | 205 Days |
Enterprise Value | $19.30B | — |
Dividend Yield | 0.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $155.01, up 0.92% with a bullish technical outlook. The stock shows strong earnings momentum with three consecutive quarterly beats and maintains solid profitability with 54.98% gross margins. Recent developments include new product launches in Europe and strategic acquisitions to expand metabolic disease research capabilities.
The investment case balances premium valuation (P/E 73.15) against consistent execution and growth initiatives. Key risks include China market pressures and margin compression, while analyst consensus remains positive with 52% buy ratings. Upside potential exists if Q3 earnings meet expectations in November.
SPY (SPDR S&P 500 ETF Trust) trades at $778.18, up 0.12% with a bullish technical signal from moving averages. The ETF shows neutral oscillator readings with RSI at 68.54 suggesting mild overbought conditions. Recent news highlights S&P 500 valuation debates and profit growth expectations of 35% for 2026. Technical support sits at $771 with resistance at $777.
Outlook remains cautiously optimistic given the ETF's broad market exposure, though risks include potential profit growth deceleration to 15% in 2027 and market-wide valuation concerns. The dividend yield of approximately 0.24% provides modest income, while institutional positioning favors large-cap stability amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About S&P500 ETF
The ETF is designed to track the performance of the securities and the stocks in the S&P 500 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on SPY →
